Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background

Neuroscience Letters

Volumn 557, Issue PB, 2013, Pages 84-89

  Lok, Kenghoe ^a   Zhao, Hong ^a   Shen, Hanlin ^a   Wang, Zejian ^a   Gao, Xiang ^b   Zhao, Wenjuan ^a   Yin, Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Amyloid ; APP PS1; Memory impairment; SAMP8

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APP PS1 GENE; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BRAIN CORTEX; CONTROLLED STUDY; FEMALE; GENOTYPE; HIPPOCAMPUS; HISTOLOGY; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MAZE TEST; MEMORY DISORDER; MOTOR ACTIVITY; MOUSE; NERVE CELL; NONHUMAN; OPEN FIELD TEST; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; SPATIAL MEMORY; TRANSGENE; WORKING MEMORY;

AMYLOID Β; APP/PS1; MEMORY IMPAIRMENT; SAMP8;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; PRESENILIN-1;

EID: 84888038649     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.10.051     Document Type: Article

References (25)

1. Apelt J., Schliebs R. β-Amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 2001, 894:21-30.
2. Butterfield D.A., Poon H.F. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp. Gerontol. 2005, 40:774-783.
3. Carrie I., Debray M., Bourre J.M., Frances H. Age-induced cognitive alterations in OF1 mice. Physiol. Behav. 1999, 66:651-656.
4. Del Valle J., Duran-Vilaregut J., Manich G., Casadesus G., Smith M.A., Camins A., Pallas M., Pelegri C., Vilaplana J. Early amyloid accumulation in the hippocampus of SAMP8 mice. J. Alzheimers Dis. 2010, 19:1303-1315.
5. Delobel P., Lavenir I., Fraser G., Ingram E., Holzer M., Ghetti B., Spillantini M.G., Crowther R.A., Goedert M. Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am. J. Pathol. 2008, 172:123-131.
6. Gonzalo-Ruiz A., Perez J.L., Sanz J.M., Geula C., Arevalo J. Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid-beta peptide in the rat. Exp. Neurol. 2006, 197:41-55.
7. Hanna A., Iremonger K., Das P., Dickson D., Golde T., Janus C. Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Alzheimers Res. Ther. 2012, 4:21.
8. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 2002, 109:813-836.
9. Jorm A.F., Korten A.E., Henderson A.S. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr. Scand. 1987, 76:465-479.
10. Knoops A.J., Gerritsen L., van der Graaf Y., Mali W.P., Geerlings M.I. Loss of entorhinal cortex and hippocampal volumes compared to whole brain volume in normal aging: the SMART-Medea study. Psychiatry Res. 2012, 203:31-37.
11. Kokjohn T.A., Roher A.E. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement. 2009, 5:340-347.
12. Lalonde R., Dumont M., Staufenbiel M., Sturchler-Pierrat C., Strazielle C. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 2002, 956:36-44.
13. Lesser J.M., Hughes S. Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options. Geriatrics 2006, 61:14-20.
14. Lyness S.A., Zarow C., Chui H.C. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol. Aging 2003, 24:1-23.
15. McNamara R.K., Skelton R.W. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res. Brain Res. Rev. 1993, 18:33-49.
16. Mitchell J.T., Nelson-Gray R.O. Attention-deficit/hyperactivity disorder symptoms in adults: relationship to Gray's behavioral approach system. Pers. Indiv. Differ. 2006, 40:749-760.
17. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
18. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 2011, 34:185-204.
19. Saul A., Sprenger F., Bayer T.A., Wirths O. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34:2564-2573.
20. Suenaga T., Hirano A., Llena J.F., Ksiezak-Reding H., Yen S.H., Dickson D.W. Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 1990, 49:31-40.
21. Takeda T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem. Res. 2009, 34:639-659.
22. Takeda T., Hosokawa M., Higuchi K. Senescence-accelerated mouse (SAM): A novel murine model of senescence. Exp. Gerontol. 1997, 32:105-109.
23. Torres C., Escarabajal M.D. Validation of a behavioral recording automated system in the elevated plus-maze test. Life Sci. 2002, 70:1751-1762.
24. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 2000, 130:184-208.
25. Walker J.M., Fowler S.W., Miller D.K., Sun A.Y., Weisman G.A., Wood W.G., Sun G.Y., Simonyi A., Schachtman T.R. Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease. Behav. Brain Res. 2011, 222:169-175.